You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
SBC: MICROBIOTIX, INC. Topic: NIAIDAbstract Segmented negative-sense, single-stranded RNA viruses (sNSVs), which include bunyaviruses, are causative agents of human diseases. Rift Valley Fever Virus (RVFV), a bunyavirus, causes hemorrhagic fever in humans with a case fatality rate of patients developing hemorrhagic fever reaching approximately 50% and has been classified by the NIAID as a Category A Priority Pathogen. RVFV is mosqu ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of Broad-Spectrum CyclicAmphiphilic Peptides against Multidrug-Resistant Bacteria
SBC: AJK BIOPHARMACEUTICAL LLC Topic: NIAIDABSTRACT The emergence of antibacterial resistance to common frontline antibiotics, such as methicillin, vancomycin, cephalosporins, and carbapenem, have created a global public health challenge for millions of patients. It is therefore critical to discover and commercialize new antimicrobial agents that can successfully neutralize multidrug-resistant bacteria (MDRB) with minimal toxicity. The obj ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of protease activity-based detector substrates for diagnosing Candida infections
SBC: BIOSYNESIS, INC. Topic: NIAIDProject Summary/Abstract Members of the Candida genus of fungi form part of the normal human microbiota but are also opportunistic pathogens capable of causing serious mucosal and systemic infections. Candida cells grow and divide in suspension (planktonic) cultures, but they also form resilient and drug resistant biofilms – organized, tightly- packed communities of cells that attach to surfaces ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: NIAIDPROJECT SUMMARY There is an urgent need for the development of new approaches to treat patients suffering from pulmonary injury from viral infections, as demonstrated by the severe impact of COVID-19, which is a global pandemic that, at the time of writing, is estimated have impacted approximately 50 million people in the United States, leading to morbidity, substantial hospital and intensive care ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
STTR Phase I:Self-healing Power Electronics for Urban Air Mobility Applications
SBC: VALCON LABS, INC. Topic: MOThe broader/commercial impact of this Small Business Innovation Research (SBIR) Phase I project is to increase safety and reduce weight and redundancies for many vehicular systems and electronic devices. This project will also enhance autonomous systems integration in terms of diagnostics and enable reconfiguration for a variety of safety-critical applications. The proposed self-healing, fault-tol ...
STTR Phase I 2023 National Science Foundation -
Translational development of novel CRISPR approach to treat genomic duplications
SBC: MYOFINITY BIOSCIENCES INC Topic: NIAMSPROJECT ABSTRACT The goal of this Phase I STTR project is to accomplish key milestones in commercializing a novel SaCas9 nickase-based system (CRD-002) to treat dystrophinopathies in order to restore the production of healthy, endogenous full-length dystrophin protein otherwise compromised by duplication mutations. Duchenne muscular dystrophy (DMD) is characterized by progressive muscle loss and c ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Exploiting translation elongation for improved biologics manufacturing
SBC: CODOMAX INC. Topic: NCATSAbstract – Codomax has developed a codon engineering platform that enables bespoke, high-yield, cost- effective protein manufacturing by leveraging a newly discovered translational regulatory system in industrially relevant cell systems. Protein manufacturing has a current estimated market size of over $300 billion, distributed among the areas of antibodies and biologic therapeutics, biotechnolo ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Closed-loop laryngeal pacing for voice restoration
SBC: RIPPLE LLC Topic: NIDCDProject Summary and Abstract The most common neurogenic voice disorder is unilateral vocal fold paralysis (UVFP), which can substantially reduce quality of life. Current available surgical treatments offer only temporary improvement in voice through placement of resorbable materials or involve permanent, invasive alteration of the larynx that incompletely restores voice and often requires revision ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Prevention and mitigation of acute traumatic coagulopathy and bleeding
SBC: HEMATHERIX LLC Topic: NHLBIProject Summary/Abstract Hematherix is developing superFVa for the treatment of acute traumatic coagulopathy (ATC). Mortality rates with traumatic hemorrhage often exceed 40%, exposing an unmet clinical need for targeted drug development. ATC develops early on as the consequence of severe trauma and shock, prior to additional iatrogenic effects. ATC is distinct from other coagulopathies and is cha ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic targeting of FKBP51 for the prevention of stress-induced preterm birth
SBC: DARE BIOSCIENCE, INC. Topic: NICHDIn the United States, one in ten babies is born prematurely. The earlier in pregnancy a baby is born, the more likely they will have an extended hospital stay, as well as serious health complications such as respiratory distress syndrome, necrotizing enterocolitis, deafness, vision problems and cerebral palsy. Maternal stress is a well-established risk factor for preterm birth, and recent studies ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health